DiscoverAllergy/Immunology – Dr. Barry DworkinUBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.
UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.

UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.

Update: 2022-03-29
Share

Description

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.

UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.

Dr. Barry Dworkin